ASTRAZEN.NSE logo

ASTRAZEN.NSE
AstraZeneca Pharma India Ltd.

195
Loading...
Loading...
News
all
press releases
AstraZeneca Pharma India bolsters oncology and market access leadership
AstraZeneca Pharma India Limited ( ($IN:ASTRAZEN) ) has shared an update. AstraZeneca Pharma India Limited has strengthened its leadership team by ...
cityfalcon.com·4d ago
News Placeholder
More News
News Placeholder
AstraZeneca Pharma India wins CDSCO approval for durvalumab
UK pharma major AstraZeneca’s majority owned Indian subsidiary, today announced that Central Drugs Standard Control Organization (CDSCO) has approved an additional indication for durvalumab solution for infusion (120mg/2.4 mL and 500mg/10 mL), for the treatment of patients with unresectable hepatocellular carcinoma (uHCC), who have not received prior systemic therapy in India.
cityfalcon.com·19d ago
News Placeholder
AstraZeneca Pharma India receives CDSCO approval for Durvalumab for patients with uHCC
AstraZeneca Pharma India, a global, science-led biopharmaceutical company, announced that Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Durvalumab solution for infusion (120 mg/2.4 mL and […] The post AstraZeneca Pharma India receives CDSCO approval for Durvalumab for patients with uHCC appeared first on Express Pharma .
cityfalcon.com·19d ago
News Placeholder
Cancer Drug Imfinzi Gets Indian Regulator's Approval For Use In Treatment
AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation to sell and distribute Durvalumab solution for infusion used in cancer... ......
cityfalcon.com·2mo ago
News Placeholder
AstraZeneca India wins CDSCO approval for Durvalumab in cancer
New Delhi, Feb 10 : AstraZeneca Pharma India Limited on Tuesday said it has received permission from the Central Drugs Standard Control Organisation (CDSCO) to sell and distribute Durvalumab solution for infusion used in cancer treatment for an additional indication. In its latest stock exchange filing, the drug company said that through this approval, “Durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR)”. According to the filing, “This is to inform that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 mL and 500 mg/10 mL (Brand Name: Imfinzi) for an additional indication,” said AstraZeneca Pharma India Ltd.
cityfalcon.com·2mo ago
<
...
1
>

Latest ASTRAZEN.NSE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.